Funds and ETFs enVVeno Medical Corporation

Equities

NVNO

US29415J1060

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-29 pm EDT 5-day change 1st Jan Change
5.22 USD +0.77% Intraday chart for enVVeno Medical Corporation +6.31% +1.56%
enVVeno Medical Corporation is a late-stage clinical med-tech company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (CVI) of the deep venous system of the leg. The Company's lead product, VenoValve, which is a porcine based replacement venous valve developed to surgically implanted in the deep venous system of the leg to treat severe CVI. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter based replacement venous valve.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
5.18 USD
Average target price
20.4 USD
Spread / Average Target
+293.82%
Consensus
  1. Stock Market
  2. Equities
  3. NVNO Stock
  4. Funds and ETFs enVVeno Medical Corporation